Copyright
©The Author(s) 2021.
World J Nephrol. May 25, 2021; 10(3): 29-36
Published online May 25, 2021. doi: 10.5527/wjn.v10.i3.29
Published online May 25, 2021. doi: 10.5527/wjn.v10.i3.29
Table 2 Patients at high risk of nephrogenic systemic fibrosis
| Risk factors for NSF |
| Patients on dialysis (hemodialysis or peritoneal dialysis) |
| Advanced or end-stage CKD (CKD 4 or 5, eGFR < 30 mL/min/1.73 m2) without dialysis |
| Acute kidney injury |
| Proinflammatory state in a patient with impaired kidney function |
| Higher doses and multiple administrations of GBCAs, within a short period of time |
- Citation: Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021; 10(3): 29-36
- URL: https://www.wjgnet.com/2220-6124/full/v10/i3/29.htm
- DOI: https://dx.doi.org/10.5527/wjn.v10.i3.29